J. Goldman & Co’s Amicus Therapeutics FOLD Stock Holding History

J. Goldman & Co’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40,500	Closed	-$433K	–	521
2024 Q3	$433K	Buy	+40,500	New	+$441K	0.01%	360
2023 Q2	–	Sell	-236,300	Closed	-$2.62M	–	417
2023 Q1	$2.62M	Buy	236,300 +141,800	+150%	+$1.75M	0.11%	193
2022 Q4	$1.15M	Buy	+94,500	New	+$1.06M	0.06%	216
2022 Q2	–	Sell	-40,500	Closed	-$384K	–	390
2022 Q1	$384K	Buy	+40,500	New	+$380K	0.02%	299
2020 Q1	–	Sell	-40,000	Closed	-$390K	–	281
2019 Q4	$390K	Buy	+40,000	New	+$366K	0.03%	226
2018 Q1	–	Sell	-50,000	Closed	-$720K	–	374
2017 Q4	$720K	Sell	50,000 -150,000	-75%	-$2.06M	0.04%	245
2017 Q3	$3.02M	Buy	+200,000	New	+$2.65M	0.15%	165
2015 Q2	–	Sell	-182,000	Closed	-$1.98M	–	269
2015 Q1	$1.98M	Buy	+182,000	New	+$1.6M	0.12%	188

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

J. Goldman & Co's FOLD Position: Q2 2023 in Review

J. Goldman & Co sold out of Amicus Therapeutics (FOLD) in Q2 2023, closing a stake of 387,654 shares — an estimated $4.3M sold.

J. Goldman & Co first reported a position in FOLD in Q4 2014 and held it in 10 quarters. The position peaked at $4.3M in Q1 2023. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

J. Goldman & Co reported no remaining Amicus Therapeutics position as of Q2 2023 after selling out during the quarter.
J. Goldman & Co sold 387,654 Amicus Therapeutics shares in Q2 2023, an estimated $4.3M.
J. Goldman & Co first reported a position in Amicus Therapeutics in Q4 2014 and held it in 10 quarters.
J. Goldman & Co's Amicus Therapeutics position peaked at $4.3M in Q1 2023.
216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.